Gilead Sciences Aktie
87,63 EUR ±0,00 EUR ±0,00 %
STU
91,09 USD -0,02 USD -0,02 %
nachbörslichBTT
BTT
Werbung
Gilead Sciences Rating
Gilead Sciences Inc. Aktie Moody's Rating
A3
C
A3
Aaa
Investmentwürdig - Hohe Sicherheit
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
Investmentwürdig - Mittlere Sicherheit
Nicht als Investment geeignet
| Rating | A3 | Rating Typ Bank Financial Strength Rating Insurance Financial Strength Rating Enhanced Rating Insured Rating Long-Term Bank Deposit Rating Long-Term OSO Rating Long-Term Debt Rating Money Market Fund Rating Modeled Shadow Rating Management Quality Rating Probability of Default Rating Pfd/Pref Stock Rating Prospective Pfd/Pref Rating Short-Term Bank Deposit Rating Speculative Grade Liquidity Rating Prospective LT Debt Rating Short-Term Insurance Financial Strength Rating Short-Term OSO Rating Servicer Quality Short-Term Debt Rating Lloyd´s Syndicate Performance Rating Underlying Rating Unknown - for conversion use only | Long-Term Debt Rating |
| Letzte Aktion | AFFIRM | Moody's Büro in | - |
Anleihen von Gilead Sciences Inc. mit Moody's Ratings
| Emittent | Anzahl Anleihen | Ratings |
|---|---|---|
| Gilead Sciences Inc. | 20 | A3 |
Moody's Ratings Peer Group
| Aktie | Rating |
|---|---|
| Amgen Inc. | Baa1 |
| AstraZeneca PLC | A2 |
| Biogen Inc | Baa2 |
| Merck Co. | A1 |
| Merck KGaA | A3 |
| Merck KGaA | Baa1 |
| Pfizer Inc. | A1 |
| Pfizer Inc. | A2 |